phytic acid has been researched along with Calcinosis in 16 studies
Phytic Acid: Complexing agent for removal of traces of heavy metal ions. It acts also as a hypocalcemic agent.
myo-inositol hexakisphosphate : A myo-inositol hexakisphosphate in which each hydroxy group of myo-inositol is monophosphorylated.
Calcinosis: Pathologic deposition of calcium salts in tissues.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Three groups were included, a control group, an InsP6 treated group (subjected to calcinosis induction by Vitamin D and nicotine and treated with standard cream with a 2% of InsP6 as potassium salt) and an InsP6 non-treated group (only subjected to calcinosis induction)." | 3.73 | Phytate (Myo-inositol hexakisphosphate) inhibits cardiovascular calcifications in rats. ( Bonnin, O; Fernandez-Palomeque, C; Fiol, M; Grases, F; Isern, B; Perello, J; Prieto, RM; Sanchis, P; Torres, JJ, 2006) |
| "SNF472 is safe and well tolerated in HD patients after 2 schemes: multiple ascending doses for 1 week and after repeated dosing of 10 mg/kg for 4 weeks." | 2.90 | A phase 1b randomized, placebo-controlled clinical trial with SNF472 in haemodialysis patients. ( Campistol, JM; Canals, AZ; Ferrer, MD; Joubert, PH; Maduell, F; Ojeda, R; Perelló, J; Salcedo, C; Torregrosa, V, 2019) |
| " The antinutrient effect of phytate results because it can decrease the bioavailability of important minerals under certain circumstances." | 2.61 | Key Aspects of Myo-Inositol Hexaphosphate (Phytate) and Pathological Calcifications. ( Costa-Bauza, A; Grases, F, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (6.25) | 18.7374 |
| 1990's | 1 (6.25) | 18.2507 |
| 2000's | 7 (43.75) | 29.6817 |
| 2010's | 5 (31.25) | 24.3611 |
| 2020's | 2 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Grases, F | 12 |
| Costa-Bauza, A | 4 |
| Torrecilla, C | 1 |
| Fernández-Concha, J | 1 |
| Cansino, JR | 1 |
| Mainez, JA | 1 |
| Amón, JH | 1 |
| Costas, S | 1 |
| Angerri, O | 1 |
| Emiliani, E | 1 |
| Arrabal Martín, MA | 1 |
| Arrabal Polo, MA | 1 |
| García, A | 1 |
| Reina, MC | 1 |
| Sánchez, JF | 1 |
| Budía, A | 1 |
| Pérez-Fentes, D | 1 |
| Cuñé, J | 1 |
| Perez, MM | 1 |
| Ferrer, MD | 2 |
| Lazo-Rodriguez, M | 1 |
| Canals, AZ | 2 |
| Banon-Maneus, E | 1 |
| Campistol, JM | 2 |
| Miller, S | 1 |
| Garg, R | 1 |
| Gold, A | 1 |
| Salcedo, C | 2 |
| Perelló, J | 10 |
| Joubert, PH | 1 |
| Maduell, F | 1 |
| Torregrosa, V | 1 |
| Ojeda, R | 1 |
| Muntaner-Gimbernat, L | 1 |
| Vilchez-Mira, M | 1 |
| Tur, F | 1 |
| Prieto, RM | 10 |
| Torrens-Mas, M | 1 |
| Vega, FG | 1 |
| Fernández-Palomeque, C | 4 |
| Grau, A | 1 |
| Sanchis, P | 6 |
| Isern, B | 6 |
| Caldés, OJ | 1 |
| Bonnin, O | 2 |
| Garcia-Raja, A | 1 |
| Bethencourt, A | 1 |
| Saus, C | 1 |
| Fiol, M | 2 |
| Estruch, R | 1 |
| Ros, E | 1 |
| WALKER, AR | 1 |
| Simonet, BM | 2 |
| Torres, JJ | 3 |
| March, JG | 1 |
| Hiasa, Y | 1 |
| Kitahori, Y | 1 |
| Morimoto, J | 1 |
| Konishi, N | 1 |
| Nakaoka, S | 1 |
| Nishioka, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Multicenter, Controlled and Randomized Clinical Trial to Evaluate the Combined Use of a Medical Device and a Food Supplement in the Control of Urinary pH in Patients With an Implanted Double Pigtail Stent[NCT03343275] | 105 participants (Actual) | Interventional | 2017-12-13 | Completed | |||
| Value of Oral Phytate (InsP6) in the Prevention of Progression of the Cardiovascular Calcifications[NCT01000233] | Phase 2/Phase 3 | 250 participants (Anticipated) | Interventional | 2009-08-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for phytic acid and Calcinosis
| Article | Year |
|---|---|
Key Aspects of Myo-Inositol Hexaphosphate (Phytate) and Pathological Calcifications.
Topics: Animals; Calcinosis; Calcium; Crystallization; Humans; Inositol Phosphates; Phytic Acid | 2019 |
3 trials available for phytic acid and Calcinosis
| Article | Year |
|---|---|
Reduction of ureteral stent encrustation by modulating the urine pH and inhibiting the crystal film with a new oral composition: a multicenter, placebo controlled, double blind, randomized clinical trial.
Topics: Administration, Oral; Adult; Calcinosis; Crystallization; Double-Blind Method; Female; Humans; Hydro | 2020 |
A phase 1b randomized, placebo-controlled clinical trial with SNF472 in haemodialysis patients.
Topics: Aged; Calcinosis; Cardiomyopathies; Cohort Studies; Dose-Response Relationship, Drug; Drug Administr | 2019 |
Effects of Mediterranean diets with low and high proportions of phytate-rich foods on the urinary phytate excretion.
Topics: Aged; Calcinosis; Colorectal Neoplasms; Cross-Sectional Studies; Diet, Mediterranean; Edible Grain; | 2010 |
12 other studies available for phytic acid and Calcinosis
| Article | Year |
|---|---|
A novel assay to measure calcification propensity: from laboratory to humans.
Topics: Animals; Aorta; Biomarkers; Calcinosis; Calciphylaxis; Calcium Phosphates; Clinical Laboratory Techn | 2020 |
Characterization of deposits in patients with calcific tendinopathy of the supraspinatus. Role of phytate and osteopontin.
Topics: Adult; Aged; Calcinosis; Durapatite; Female; Humans; Male; Middle Aged; Osteopontin; Phytic Acid; Re | 2015 |
Relationship between Urinary Level of Phytate and Valvular Calcification in an Elderly Population: A Cross-Sectional Study.
Topics: Aged; Aging; Calcification, Physiologic; Calcinosis; Cardiomyopathies; Cross-Sectional Studies; Diab | 2015 |
Phytate reduces age-related cardiovascular calcification.
Topics: Administration, Oral; Aging; Animal Feed; Animals; Aorta; Aortic Diseases; Calcinosis; Cardiovascula | 2008 |
Cereals, phytic acid and calcification.
Topics: Calcinosis; Calcium; Edible Grain; Humans; Phytic Acid | 1951 |
Dietary myo-inositol hexaphosphate prevents dystrophic calcifications in soft tissues: a pilot study in Wistar rats.
Topics: Administration, Oral; Animals; Calcinosis; Diet; Disease Models, Animal; Etidronic Acid; Injections, | 2004 |
Absorption of myo-inositol hexakisphosphate (InsP6) through the skin: study of the matrix effects. mechanism of phytate topical absorption.
Topics: Administration, Topical; Aging; Animals; Calcinosis; Dermatology; Gastrointestinal Tract; Male; Phyt | 2005 |
Study of a myo-inositol hexaphosphate-based cream to prevent dystrophic calcinosis cutis.
Topics: Administration, Cutaneous; Animals; Calcinosis; Male; Ointments; Phytic Acid; Potassium Permanganate | 2005 |
Phytate (Myo-inositol hexakisphosphate) inhibits cardiovascular calcifications in rats.
Topics: Animals; Aorta; Calcification, Physiologic; Calcinosis; Calcium; Calcium Metabolism Disorders; Cardi | 2006 |
Effect of crystallization inhibitors on vascular calcifications induced by vitamin D: a pilot study in Sprague-Dawley rats.
Topics: Animals; Aorta; Atherosclerosis; Bone Density Conservation Agents; Calcinosis; Calcium; Crystallizat | 2007 |
Phytate prevents tissue calcifications in female rats.
Topics: Animal Feed; Animals; Calcinosis; Calcium; Dietary Supplements; Female; Kidney; Kidney Diseases; Mag | 2000 |
Carcinogenicity study in rats of phytic acid 'Daiichi', a natural food additive.
Topics: Animals; Calcinosis; Female; Food Additives; Kidney; Kidney Diseases; Kidney Neoplasms; Male; Necros | 1992 |